AUTHORS
Elias Jabbour, MD, Jae H Park, MD2, Karamjeet Singh Sandhu, MD3, Aaron C. Logan, MD, PhD, MPhil4, Bijal Shah, MD, MS5, Eleni Tholouli, MD, PhD, FRCPath6, Paul Shaughnessy, MD7, Pere Barba, MD, PhD8, Manuel Guerreiro9, Deborah Yallop10, Mehrdad Abedi, MD11, Michael R. Bishop, MD12, Daniel J DeAngelo, MD, PhD13, Karl S. Peggs14, Pierre Lao-Sirieix, PhD15, Ping Wang16, Ram Malladi17, Claire Roddie, MBChB, PhD18
AFFILIATIONS
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California San Francisco, San Francisco, California, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Manchester Royal Infirmary, Manchester, United Kingdom
7 Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, Texas, United States
8 Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain
9 Hospital Universitari i Politècnic La Fe, Valencia, Spain
10 King’s College Hospital NHS Foundation Trust, London, United Kingdom
11 University of California Davis, Davis, California, United States
12 The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 University College London Cancer Institute, London, United Kingdom
15 Autolus Therapeutics, London, United Kingdom
16 Autolus Therapeutics, Rockville, Maryland, United States
17 Autolus Therapeutics, London, United Kingdom
18 University College London Cancer Institute, London, United Kingdom
ABSTRACT
BACKGROUND: Obe-cel is an autologous 4-1BB-ζ CD19-directed CAR T-cell therapy with a fast off-rate binding domain, designed to enhance persistence and mitigate severe immunotoxicity. In FELIX (NCT04404660), 99/127 patients (pts; 78%) with R/R B-ALL who were infused with obe-cel achieved complete remission (CR) or CR with incomplete hematologic recovery, and 38 (38%) remained in remission after nearly 3 years without additional anti-cancer therapy. Although cytopenias are commonly observed following CAR T-cell therapy in R/R B-ALL, their evolution alongside treatment response has not been well characterized. Here, we evaluated efficacy, safety and hematologic recovery during the first 3 months (mos) after infusion, to define early clinical expectations following obe-cel treatment.
METHODS: In FELIX, adult pts (≥18 yrs) with R/R B-ALL were treated with obe-cel at a total target dose of 410×106 CAR T-cells. The timing of MRD response (Month [M] 1 and M3) by central ClonoSEQ NGS (MRD-negative: <10−6 leukemic cells; MRD-positive: ≥10−6 leukemic cells) and event-free survival (EFS) were used to evaluate efficacy. Incidence and severity of adverse events, including CRS, ICANS, infections and changes in hematologic parameters, were used to evaluate safety. Toxicity was graded using NCI CTCAE v5.0, except for CRS and ICANS, for which the ASTCT/ASBMT consensus guidelines were used. Laboratory data were collected at leukapheresis, prior to lymphodepletion, Day 1, 8, 15, 22, M1, M2, M3, M4, M6, then every 3 months until M24. Time-to-event outcomes were summarized using Kaplan-Meier methodology. Neutrophil and platelet count recovery to ≥0.5×109/L and ≥50×109/L, respectively, are reported below. The median study follow-up was 32.8 months (range: 19.9–52.8).
RESULTS: Among 99 responders, 68 were evaluable for NGS MRD assessment; 41 (60%) achieved MRD-negative remission by M1. Sixteen additional pts achieved MRD-negative remission between M1 and M3, including eight pts who converted from MRD-positive disease and eight with previously unconfirmed MRD status. Regardless of the timing of MRD response, long-term follow-up revealed comparable 24-month EFS rates among pts who achieved MRD negativity (n/N=57/68). Grade ≥3 CRS and ICANS were observed in 2.4% and 7.1% of infused pts, respectively, with most occurring within M1 and all resolved by M3. By M3, 23% of responders had experienced Grade ≥3 infections. In terms of hematologic parameters, Grade 4 neutropenia (neutrophil counts <0.5×109/L) was present in 20% of all responders at screening, increasing to 55% pre-obe-cel infusion, and 91% after infusion. Despite this, median time to neutrophil count recovery was 0.7 mos (95% CI: 0.5–0.9), with recovery achieved in 65% and 97% of pts by M1 and M3, respectively. Grade ≥3 thrombocytopenia (platelet counts <50×109/L) was present in 25% of responders at screening, 33% pre-obe-cel infusion, and 64% after infusion. Median time to platelet count recovery was also 0.7 mos (95% CI: 0.3–1.7), with recovery in 58% and 88% of pts by M1 and M3, respectively. Neutropenia and thrombocytopenia recovery by M1/M3 respectively was less frequently observed in pts with neutrophil counts <0.5×109/L (recovered by M1/M3: 35%/83% vs 73%/100%) and platelet counts <50×109/L (recovered by M1/M3: 40%/65% vs 64%/95%) at screening vs pts with counts above the threshold, respectively. A higher proportion of pts with <5% bone marrow (BM) blasts at screening recovered counts by M1 vs pts with ≥5% BM blasts at screening (neutrophil recovery: 93% vs 60%; platelet recovery: 82% vs 53%), although by M3 most pts had recovered regardless of baseline disease burden (neutrophils: 100% vs 97%; platelets: 94% vs 87%). Fewer patients recovered neutrophil counts by M1 following chemotherapy-based vs inotuzumab-containing bridging therapy (57% vs 87%); the opposite was observed with recovery of platelet counts (57% vs 40%).
CONCLUSIONS: MRD responses continued to deepen beyond M1, with pts who achieved delayed MRD negativity experiencing outcomes comparable to early responders. Most pts recovered neutrophil and platelet counts within 3 mos, although prolonged cytopenias were more frequent in pts with high baseline disease burden and lower pre-treatment blood counts. Differences in hematologic recovery according to bridging strategy were also observed. These findings may help define early clinical expectations following obe-cel treatment and inform patient management strategies.
DISCLOSURES
Elias Jabbour, MD: Ascentage - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen Inc. - Honoraria; Taiho - Honoraria; Novartis - Honoraria; TGRX Pharmaceuticals - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Gilead/Kite - Honoraria; TERN - Honoraria; Autolus - Honoraria; Amgen Inc. - Research Funding; AbbVie - Research Funding; Autolus - Research Funding; Takeda - Research Funding; Pfizer - Research Funding; Taiho - Research Funding; TGRX Pharmaceuticals - Research Funding; Gilead/Kite - Research Funding; Ascentage - Research Funding; Allotera - Research Funding; Novartis - Research Funding; Adaptive Biotechnologies - Research Funding; TERN - Research Funding; Amgen Inc. - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); TGRX Pharmaceuticals - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Taiho - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); TERN - Consultancy (Includes expert testimony)